secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-06-12T11:10:43+00:00
Accession:  0001140361-26-024997
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharmaceuticals closes sale of rare pediatric disease PRV for $180M
--------------------------------------------------------------------------

- Closed sale of Rare Pediatric Disease PRV to large pharma for gross proceeds of $180M.
- PRV was granted by FDA in March 2026 with approval of KRESLADI for severe LAD-I.
- Pro forma cash, cash equivalents, and investments total ~$322.6M, extending runway into Q2 2028.
- Previously reported cash of $144.4M as of March 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/0001140361-26-024997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/ef20076119_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-024997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer